BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-102@catalystbrief.girapphe.com
DTSTAMP:20261117T121554Z
LAST-MODIFIED:20261117T121554Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Acerta Pharma BV — acalabrutinib [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Combination of Acalabrutinib With
  R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312).\
 nSource: https://clinicaltrials.gov/study/NCT04529772\nhttps://catalystbri
 ef.girapphe.com/e/102?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/102?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
